Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
8/19/2024 | $211.00 | Neutral | MoffettNathanson | |
8/2/2024 | $195.00 → $203.00 | Hold | Maxim Group | |
8/2/2024 | $205.00 → $245.00 | Buy | Monness Crespi & Hardt | |
7/29/2024 | $220.00 → $250.00 | Buy | TD Cowen | |
7/26/2024 | $7.00 | Buy | Citigroup | |
7/24/2024 | $245.00 → $265.00 | Overweight | JP Morgan | |
7/15/2024 | $216.00 → $273.00 | Overweight | Morgan Stanley | |
7/15/2024 | $170.00 → $300.00 | Hold → Buy | Loop Capital |
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a
Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form
Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird increased Apple Inc. (NASDAQ:AAPL) price target from $200 to $240. Baird analyst William Power maintained an Outperform rating. Apple shares fell 0.1% to trade at $218.51 on Thursday. See how other analysts view this stock. Truist Securities raised the price target for ServiceNow, Inc. (NYSE:NOW) from $750 to $780. Truist Securities analyst Joel Fishbein maintained a Hold rating. ServiceNow shares gained 11.9% to trade at $817.75 on Thursday. See how other analysts view this stock. JP Morg
"Hedging Is Gaining Traction" That's what Goldman Sachs's flow of funds guru Scott Rubner said in his note earlier today ("I Am Not Buying This Dip"). He also pointed out that four of the Magnificent Seven mega caps are reporting earnings next week: Microsoft Corporation (NASDAQ:MSFT), Meta Platforms, Inc. (NASDAQ:META), Apple, Inc. (NASDAQ:AAPL), and Amazon.com, Inc. (NASDAQ:AMZN), and that if their results and guidance are not "great", those stocks will likely get punished in this market environment. In the video below, I show inexpensive ways of hedging Microsoft and Meta ahead of their earnings next week. I mention a couple of times there that there's a link to download the newly
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021. On July 17 of this year, the Board appointed him Executive Chairman of the Board and the Company's principal executive officer and while undertaking a now completed search for a permanent CEO. In keeping with the company's pledge to follow good governance principles, the Company is separating the positions of CEO and Chairman by appointing Cla
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Summary of Distribution Announcements 16 tax-exempt municipal funds announced increases to their monthly distribution amounts per share BlackRock Energy and Resources Trust ("BGR") announced an increase to its monthly distribution amount per share Each Fund declared its October distribution early BlackRock Enhanced Equity Dividend Trust ("BDJ") also declared its November distribution early in order to satisfy the Fund's remaining December 31, 2023 distribution requirements The Funds' monthly distributions for October and, in the case of BDJ, November can be found below: Tax-Exempt M
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (NASDAQ:BIIB) Board of Directors (the "Board") today announced the appointments of two new independent directors, Lloyd B. Minor, M.D., effective October 1, 2024, and Sir Menelas (Mene) Pangalos, Ph.D., effective January 1, 2025. Dr. Minor is currently the Dean of the Stanford University School of Medicine and Vice President for Medical Affairs at Stanford University, and Prof Sir Pangalos was most recently Executive Vice President of Biopharmaceuticals R&D at AstraZeneca until his retirement in April 2024. "We welcome Lloyd and Mene to our Board as they add significant experience and proven track records in leading R&D
Apple Watch delivers new sleep apnea notifications, and AirPods Pro 2 provide the world's first all-in-one hearing health experience including a clinical-grade, over-the-counter Hearing Aid feature Apple® today unveiled breakthrough sleep and hearing health features coming to Apple Watch® and AirPods Pro® 2 that further deliver on Apple's commitment to health with experiences that enrich users' lives. These new features expand across products, bringing informative and powerful ways to support users in their sleep and hearing health for conditions that impact billions globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2024090
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
8-K - BIOGEN INC. (0000875045) (Filer)
10-Q - Alzamend Neuro, Inc. (0001677077) (Filer)
MoffettNathanson initiated coverage of Apple with a rating of Neutral and set a new price target of $211.00
Maxim Group reiterated coverage of Apple with a rating of Hold and set a new price target of $203.00 from $195.00 previously
Monness Crespi & Hardt reiterated coverage of Apple with a rating of Buy and set a new price target of $245.00 from $205.00 previously
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13D/A - Longeveron Inc. (0001721484) (Subject)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Summary of Distribution Announcements 16 tax-exempt municipal funds announced increases to their monthly distribution amounts per share BlackRock Energy and Resources Trust ("BGR") announced an increase to its monthly distribution amount per share Each Fund declared its October distribution early BlackRock Enhanced Equity Dividend Trust ("BDJ") also declared its November distribution early in order to satisfy the Fund's remaining December 31, 2023 distribution requirements The Funds' monthly distributions for October and, in the case of BDJ, November can be found below: Tax-Exempt M
N-CSRS - BlackRock Enhanced Global Dividend Trust (0001320375) (Filer)
Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: Declaration- 9/3/2024 Ex-Date- 9/16/2024 Record- 9/16/2024 Payable- 10/1/2024 National Funds Ticker Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.052500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.043500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Fund, Inc.* MUI $0.055000 - BlackRock Municipal Income Trust* BFK $0.050000 -